They reduce formation of P-Y-STAT1 and IFN-β-induced MxA production in vitro and in vivo (32), and allow attacks of MS when added to ongoing IFN-β-1a therapy (33) (below). The gene discussed is STAT1; the disease is myeloid sarcoma.